Serviços Personalizados
Journal
Artigo
Indicadores
- Citado por SciELO
- Acessos
Links relacionados
- Similares em SciELO
Compartilhar
Revista de investigación clínica
versão On-line ISSN 2564-8896versão impressa ISSN 0034-8376
Resumo
BANDALA-JACQUES, Antonio et al. Prognostic Significance of the MAD1L1 1673 G:A Polymorphism in Ovarian Adenocarcinomas. Rev. invest. clín. [online]. 2020, vol.72, n.6, pp.372-379. Epub 09-Abr-2021. ISSN 2564-8896. https://doi.org/10.24875/ric.19003280.
Background:
Ovarian cancer is the most lethal gynecologic cancer. Although most patients respond adequately to the first-line therapy, up to 85% experience a recurrence of disease, which carries a poor prognosis. Mitotic arrest deficiency 1 is a protein that helps in the assembly of the mitotic spindle assembly checkpoint by preventing anaphase until all chromatids are properly aligned. A single-nucleotide polymorphism in the MAD1L1 gene is prevalent in patients with advanced epithelial ovarian cancer and alters the way in which it responds to chemotherapy.
Objective:
The objective of the study was to study the relationship between the rs1801368 polymorphism of MAD1L1 and prognosis of ovarian adenocarcinoma.
Methods:
A total of 118 patients in whom the MAD1L1 gene was sequenced were analyzed using descriptive and comparative statistics.
Results:
Patients carrying the wild-type genotype had a higher distribution of early-stage disease. Having a MAD1L1 polymorphic allele increased the risk of being non-sensitive to chemotherapy. The median disease-free survival for patients with the wild-type MAD1L1 was 46.93 months, compared to 10.4 months for patients with at least one polymorphic allele.
Conclusions:
The rs1801368 polymorphism of MAD1L1 gene worsens prognosis in patients with ovarian adenocarcinoma. Traditional therapy for ovarian cancer might not be optimal in patients carrying this polymorphism.
Palavras-chave : Neoplasm; Ovarian; Genetic polymorphism; Chemotherapy.